Teva Pharmaceutical Industries Ltd (TEVA) stock
TEVANYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 7/30127% above fair value
$42.57−1.93 (-4.34%)
Close on Nov 16, 2026Market cap $49.61BP/E 71.0Yield –
Teva Pharmaceutical Industries pe ratio
The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.
Teva Pharmaceutical Industries's pe ratio was 70.7× on Nov 10, 2026, against 44.8× a year earlier. Over the last 5 years it ranged from 12.1× to 77.1×, with a median of 27.9×.
PE Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 10, 2026 | 70.7× | +18.6 |
| 2025 | Dec 31, 2025 | 52.0× | +29.1 |
| 2022 | Apr 29, 2022 | 22.9× | +10.8 |
| 2021 | Dec 31, 2021 | 12.1× | −7.3 |
| 2017 | Jan 31, 2017 | 19.4× | −1.6 |
| 2016 | Dec 30, 2016 | 21.1× | −10.6 |
| 2015 | Dec 31, 2015 | 31.7× | +13.8 |
| 2014 | Dec 31, 2014 | 17.9× | −10.3 |
| 2013 | Dec 31, 2013 | 28.2× | +12.9 |
| 2012 | Dec 31, 2012 | 15.3× | +3.3 |
| 2011 | Dec 30, 2011 | 12.0× | −4.1 |
| 2010 | Dec 31, 2010 | 16.1× | −42.4 |
| 2009 | Dec 31, 2009 | 58.5× | – |
See a number that looks wrong?